



Consolidated Financial Results for the Fiscal Year Ended March 31, 2012 [Based on Japanese GAAP]

May 14, 2012

Name of Listed Company: Meiji Holdings Co., Ltd. Listed exchange: 1st Section, Tokyo Stock Exchange
 Code Number: 2269 URL: www.meiji.com
 Representative: Naotada Sato, President and Representative Director
 Inquiries: Takashi Umemoto, General Manager, PR & IR Department
 Telephone: +81-3-3273-3917

Scheduled date of annual shareholders meeting: June 28, 2012

Scheduled date of submission of the securities report: June 28, 2012

Scheduled date of dividend payment commencement: June 8, 2012

Preparation of explanatory material for full-term financial results: Yes

Holding of a briefing on full-term financial results: Yes (a briefing for analysts and institutional investors)

(Amounts are rounded down to the nearest million yen.)

1. Consolidated Financial Results for FYE 2012/3 (April 1, 2011 to March 31, 2012)

(1) Consolidated operating results

(% of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
FYE 2012/3	1,109,275	-0.2	20,189	-32.6	21,882	-28.1	6,805	-28.8
FYE 2011/3	1,111,000	0.4	29,959	4.1	30,451	7.5	9,552	-27.0

(Note) Comprehensive income: FYE 2012/3: 8,755 million yen (81.3%)
 FYE 2011/3: 4,828 million yen (-71.7%)

	Net Income per Share	Diluted Net Income per Share	Return on Equity	Ordinary Income/Total Assets	Operating Income/Net Sales
	Yen	Yen	%	%	%
FYE 2012/3	92.38	—	2.3	3.0	1.8
FYE 2011/3	129.63	—	3.3	4.2	2.7

(Reference) Equity in income of affiliates: FYE 2012/3: 353 million yen
 FYE 2011/3: 251 million yen

(2) Consolidated financial position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	Millions of yen	Millions of yen	%	Yen
FYE 2012/3	749,985	298,491	38.9	3,958.24
FYE 2011/3	716,368	293,530	40.2	3,906.36

(Reference) Shareholders' equity: FYE 2012/3: 291,589 million yen
 FYE 2011/3: 287,782 million yen

(3) Consolidated cash flows

	Cash Flows from Operating Activities	Cash Flows from Investing Activities	Cash Flows from Financing Activities	Cash and Cash Equivalents at Year-End
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
FYE 2012/3	30,597	-44,314	4,861	14,363
FYE 2011/3	57,995	-32,440	-19,570	21,741

2. Dividends

	Cash Dividends Per Share					Total Cash Dividends (annual)	Payout Ratio (Consolidated)	Dividends to Net Assets Ratio (Consolidated)
	End of First Quarter	End of Second Quarter	End of Third Quarter	Year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
FYE 2011/3	–	40.00	–	40.00	80.00	5,996	61.7	2.0
FYE 2012/3	–	40.00	–	40.00	80.00	5,893	86.6	2.0
FYE 2013/3 (Projected)	–	40.00	–	40.00	80.00		49.9	

3. Forecasts of Consolidated Financial Results for FYE 2013/3 (April 1, 2012 to March 31, 2013)

(% of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income		Net Income per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
FYF 2013/3 1st Half	560,000	2.2	8,000	7.9	9,000	3.8	4,300	82.2	58.37
FYE 2013/3 Full Year	1,125,000	1.4	24,000	18.9	24,000	9.7	11,800	73.4	160.18

*Notes

(1) Changes in significant subsidiaries during the fiscal year under review

(Changes in subsidiaries affecting the scope of consolidation): None

(2) Changes in accounting policy, changes in accounting estimates, restatements

1. Changes in accounting policy due to revisions of accounting standards: None

2. Other changes in accounting policy: None

3. Changes in accounting estimates: None

4. Restatements: None

(3) Number of shares outstanding (common stock)

1. Number of shares outstanding at end of period (including treasury stock)	FYE 2012/3	76,341,700 shares	FYE 2011/3	76,341,700 shares
2. Number of treasury stock at end of period	FYE 2012/3	2,675,306 shares	FYE 2011/3	2,671,471 shares
3. Average number of shares during period	FYE 2012/3	73,668,186 shares	FYE 2011/3	73,688,574 shares

* Indication regarding the implementation of financial review procedures

This financial results report is not subject to the review procedures prescribed by the Financial Instruments and Exchange Act. At the time of the disclosure of this financial results report, the review procedures prescribed by the Financial Instruments and Exchange Act had not been completed.

* Forward-looking statements and other special notes

(Notice concerning forward-looking statements)

The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of this presentation and reasonable assumptions made by the Company. Actual results could differ materially from forecasts due to various factors. For earnings forecasts assumptions and other related items, please refer to “1. Operating Results, (1) Analysis of Operating Results, (iii) Forecasts for the Fiscal Year ending March 31, 2013” (page 8).

(Explanatory material for financial results)

The explanatory material for financial results is disclosed through TDnet together with these financial statements. It is also posted on our website on the same day.

1. Operating Results

(1) Analysis of Operating Results

(Millions of yen)

	Net Sales	Operating Income	Ordinary Income	Net Income	Net Income per Share (Yen)
FYE 2012/3	1,109,275	20,189	21,882	6,805	92.38
FYE 2011/3	1,111,000	29,959	30,451	9,552	129.63
% of YoY Change	-0.2	-32.6	-28.1	-28.8	—

(Reference)

(Millions of yen)

	Net Sales	Operating Income	Ordinary Income	Net Income	Net Income per Share (Yen)
Forecasts for FYE 2012/3 (announced on Feb. 13)	1,105,000	18,000	19,000	6,500	88.23
Compared to plan (%)	+0.4	+12.2	+15.2	+4.7	—

In the consolidated fiscal year under review, Japan's economy continued to make a slow but steady recovery from the Great East Japan Earthquake, and business gradually picked up. The economy, however, faced uncertainties due to the effects of deflation, the prolonged appreciation of the yen, and concerns of a global economic recession resulting from the European debt crisis, etc.

Amid these circumstances, Meiji Holdings, through a corporate restructuring implemented on April 1, 2011, reorganized its two operating companies into "Meiji Co., Ltd." and "Meiji Seika Pharma Co., Ltd.," thereby shifting to a new group management structure.

Taking into consideration the extensive damage caused by the earthquake and the impact on each business segment, the Meiji Group revised downward its sales and income forecasts. To ensure a swift and steady recovery, we planned for the "recovery of lost regions" and "solidification" in the first half, and the resumption of normal operations at pre-quake levels in the second half. We then made our utmost efforts to accomplish these goals while simultaneously building and strengthening our new group management structure.

Below is an overview by segment.

[Food segment]

The food segment saw an early recovery of confectionery and functional healthcare products, producing results almost on par with normal years, but fresh dairy products (such as milk and yogurt) and enteral formula which had sustained extensive damage, steadily regained market share in the second half, and achieved a general recovery according to plan. This improvement, however, did not compensate for the damage in the first half. As a result, net sales and operating income were below the previous fiscal year's level.

[Pharmaceuticals segment]

Mainstay antibacterial drugs and antidepressants showed a solid performance, and strong sales of newly launched products boosted sales of generic drugs, which contributed to the segment's results. Consequently, net sales and operating income showed year-on-year growth. The agricultural chemicals and veterinary drugs businesses achieved a strong performance on the whole, due to the launch of new agricultural chemicals, etc. Accordingly, both net sales and operating income rose above the previous year's levels.

As a result, for the consolidated fiscal year under review, the Company reported net sales of 1,109,275 million yen (down 0.2% year on year), operating income of 20,189 million yen (down 32.6% year on year), ordinary income of

21,882 million yen (down 28.1% year on year), and net income of 6,805 million yen (down 28.8% year on year) after accounting for extraordinary losses relating to the earthquake, etc.

Compared to the results forecast announced on February 13, 2012, net sales were almost the same as forecasted, while operating income and ordinary income results exceeded the forecast.

[Outline of Segments (Consolidated)]

(Millions of yen)

	Reporting Segments		Total	Adjustments	Amount Presented in Statements of Income
	Food	Pharmaceuticals			
Net Sales	986,319	125,274	1,111,593	-2,318	1,109,275
Operating Income	11,491	8,186	19,678	511	20,189

(Note)

The reporting segments were changed to the “Food” and “Pharmaceuticals” segments.

(i) Food segment (corresponds to the business of Meiji Co., Ltd.)

(Millions of yen)

	FYE 2011/3	FYE 2012/3	% of YoY Change
Net Sales	988,854	986,319	-0.3
Operating Income	22,322	11,491	-48.5

(Note)

The actual figures for the fiscal year ended March 31, 2011, have been presented, assuming for the sake of comparison that the new segmentation had been applied from the start of that fiscal year.

Below is an overview of each of this segment’s main businesses.

- Dairy business (Fresh dairy: Drinking milk, yogurt, beverages, etc.; Processed dairy food products: cheese, butter, dairy products for professional use, etc.)

Fresh Dairy

Drinking milk had a difficult first half, due to a suspension in sales of mainstay products immediately after the earthquake, etc. But from the start of the second half, fresh dairy showed a firm recovery. Yogurt also steadily recovered in the second half, achieving full-year results on par with the previous year. Since January of this year, “Meiji Yogurt R-1” has also contributed to this segment’s sales growth, primarily because its health value was reported in various media.

Processed dairy food products

In natural cheese for the fresh dairy market, our mainstay “Meiji Tokachi Camembert Cheese” steadily recovered in the second half, while net sales of “Meiji Buono Cheese” grew due to expansion of the sales regions for this product. Sales of margarine for the fresh dairy market exceeded the previous year’s level, partly due to the strength of “Meiji Healthy Soft *Offstyle*,” launched in March 2011.

- Confectionery business (Confectioneries: Chocolate, chewing gum, candy, imported confectioneries, etc.; Desserts: Ice cream, sweets, etc.; Institutional food products: Confectioneries, other food products, etc.)

Confectionery

Chocolate sales far exceeded the previous year’s level, due to the long-selling “Almond Chocolate” and aggressive brand development efforts for “Galbo” and “Melty Kiss.” In contrast, sales of “Xylish Gum” in the chewing gum category marked a large year-on-year decline, due in part to a depressed market.

Desserts

In ice cream, sales of our mainstay “Meiji Essel Super Cup” showed year-on-year growth. We also actively launched new products that included “Chocolate Ice Cream Bar” and “Dorea.”

We launched the new “Crispy’s” brand for both the confectionery and desserts categories in March 2012. This simultaneously expanded our lineup for chocolate and ice cream, as part of our efforts to meet new customer needs.

Institutional Food Products

Although there was significant damage to some parts of the operations immediately after the earthquake, both Confectioneries and Other Food Products showed a relatively strong performance as a result of aggressive business development efforts.

- Healthcare and Nutritionals business (Healthcare: Sports nutrition, functional healthcare products, food, OTC drugs, etc.); Nutritionals: (Powdered milk, enteral formula, nursing care foods, etc.)

Healthcare

Sales of “Amino Collagen” rose year on year, and sales of “SAVAS” also grew, benefiting from the surge in the popularity of jogging.

Nutritionals

Enteral formula production was severely impacted by the earthquake in the first half, but a recovery of production and supply capacity enabled the achievement of results on par with the previous year. Sales of powdered milk fell far below the previous year’s level, affected by falling demand due to the encouragement of breast feeding and the disappearance of the bulk buying that was seen immediately after the earthquake; sales were also negatively affected by our voluntary replacement of “Meiji Step” in December 2011.

(ii) Pharmaceuticals segment (corresponds to the business of Meiji Seika Pharma Co., Ltd.)

(Millions of yen)

	FYE 2011/3	FYE 2012/3	% of YoY Change
Net Sales	124,202	125,274	+0.9
Operating Income	7,522	8,186	+8.8

(Note)

The actual figures for the fiscal year ended March 31, 2011, have been presented, assuming for the sake of comparison that the new segmentation had been applied from the start of that fiscal year.

A summary of the Pharmaceuticals segment is as follows.

■ Ethical Pharmaceuticals

In antibacterial drugs, “MEIACT” maintained net sales on par with the previous year’s level, while “ORAPENEM” showed year-on-year growth in sales.

In antidepressants, sales of “DEPROMEL” declined year on year, due in part to the impact of the launch of generic drugs. But sales of “REFLEX” showed a significant growth in sales, due to the active promotion of this drug in the scientific and academic fields.

In our generic drugs business, sales of the “AMLODIPINE TABLETS MEIJI” calcium channel blocker showed large growth over the previous year. In addition, a favorable performance by the “Pioglitazone MEEK” insulin-sensitizing agent launched in June 2011 and the “DONEPEZIL MEIJI” remedy for Alzheimer-type dementia launched in November 2011 also contributed to sales.

We signed a “Strategic Partnership Agreement on Biosimilars” with Korea’s Dong-A Pharmaceutical in September 2011. This is part of our active efforts to pursue alliances as a means of strengthening our business in preparation for future growth. .

■ Agricultural Chemicals (Agricultural chemicals and veterinary drugs)

In agricultural chemicals, sales of our mainstay “ORYZEMATE” rice blast preventative rose year on year, and our “ZAXA” liquid formula foliage herbicide launched in April 2011 also contributed to sales in this segment. Thus, the segment, as a whole, showed an improved performance over the previous year.

Veterinary drugs saw a year-on-year rise in net sales of companion animal drugs. However, sales of livestock drugs and fishery veterinary drugs declined. As a result, overall sales for this segment remained on par with the previous year’s level.

(iii) Forecasts for the Fiscal Year ending March 31, 2013

In the period of the “FY2009-2011 Medium-Term Business Plan,” we took the April 2009 management integration as an opportunity to establish our “Meiji Group’s System of Principles” and “New Brand Logo.” We announced our “Meiji Group 2020 Vision” (hereinafter referred to as the “2020 Vision”) in September 2010. We also reorganized our group operating subsidiaries into “Meiji Co., Ltd.,” a food company, and “Meiji Seika Pharma Co., Ltd.,” a pharmaceutical company, and introduced a new management structure in April 2011. Although we showed a deterioration in our earnings performance in the term under review, we have made progress in preparing our organization for future growth and development.

In fiscal year 2012, ending March 31, 2013, we launched the “FY2012-2014 Medium-Term Business Plan,” named “TAKE OFF 14.” This plan, aimed at achieving the goals of our 2020 Vision, has as its priority theme “higher profitability and strategic investment to leap forward.” Under this plan, we intend to strengthen and expand existing businesses, foster growth businesses, work on boosting profitability, and reach net sales of 1,190 billion yen, operating income of 40 billion yen, and an ROE of 7% by fiscal year 2014, ending March 31, 2015.

We plan to announce the details of the “TAKE OFF 14” on May 21, 2012, and these details will also be disclosed on our website.

Our consolidated forecasts for fiscal year 2012 (the fiscal year ending March 2013)—the first year of the “TAKE OFF 14”—are net sales of 1,125 billion yen, operating income of 24 billion yen, ordinary income of 24 billion yen, and net income of 11.8 billion yen.

(Millions of yen)

	Net Sales	Operating Income	Ordinary Income	Net Income	Net Income per Share (Yen)
FYE 2013/3 (Forecasts)	1,125,000	24,000	24,000	11,800	160.18
FYE 2012/3 (Results)	1,109,275	20,189	21,882	6,805	92.38
% of YoY Change	+1.4	+18.9	+9.7	+73.4	—

Results forecasts and major initiatives by segment are as follows.

(Millions of yen)

	Reporting Segments			Adjustments	Amount Presented in Statements of Income
	Food	Pharmaceuticals	Total		
Net Sales	1,000,000	128,300	1,128,300	-3,300	1,125,000
% of YoY Change	+1.4	+2.4	+1.5	—	+1.4
Operating Income	18,400	5,400	23,800	200	24,000
% of YoY Change	+60.1	-34.0	+20.9	—	+18.9

■ Food Segment

In addition to dramatically strengthening our broad range of existing businesses, we will work to foster growth businesses, and provide strong support for the initiatives implemented by each business to achieve our “TAKE OFF 14.”

Dairy Business

We will continue to strengthen the mainstay brand groups that have received active investment of management resources, such as “Meiji Oishii Gyunyu,” which is celebrating its 10th anniversary, “Meiji Bulgaria Yogurt,” and “Meiji Probio Yogurt LG21.” We will make extensive efforts to gain acceptance in the market and expand our market share for “Meiji Yogurt R-1,” “Meiji Buono Cheese,” and our new margarine products “Meiji Healthy Soft

Offstyle” among others. We are also working to boost profitability, by reviewing sales promotion expenses, improving the profits of sales subsidiaries, etc.

Confectionery Business

We will strengthen chocolate through solid initiatives for long-sellers such as “Almond Chocolate” and “Milk Chocolate,” which are approaching their 50th anniversaries. We will also work for a recovery in chewing gum driven by “Xylish Gum,” and to create and deliver new value in ice cream and sweets. We will review various costs and other factors, such as more efficient production, supply/demand and distribution, as we continue working to improve our earnings structure.

Healthcare and Nutritionals Business

We will make strenuous efforts to promote our growth strategy and strengthen our earnings structure. We will work to further solidify our mainstay brands, such as “Amino Collagen,” which is approaching its 10th anniversary. We will strengthen our “SAVAS” and “VAAM” sports nutrition products, and our medical nutrition business (enteral formula, etc.). In powdered milk, we will work to achieve a recovery in sales and rebuild our earnings structure, in addition to strengthening and expanding our “Raku Raku Cube” series.

International Business

In the priority areas of China, Asia and the USA, we will expand our businesses and improve and bolster profitability, by strengthening our brand power, technology capabilities, and marketing, etc. We will also launch a dairy business in Suzhou, China in fiscal year 2012, to deliver high-quality and tasty “meiji” brand products to our Chinese customers.

■ Pharmaceuticals Segment

As a “Speciality and Generic Pharmaceuticals Company” possessing international development capabilities, we will solidly implement important policies towards the achievement of our “TAKE OFF 14” focusing on the three main fields of anti-infective drugs, drugs for central nervous system (CNS) disorders, and generic drugs.

Ethical Pharmaceuticals

We will work to increase sales by taking the appropriate steps to widely promote “REFLEX,” “ORAPENEM,” and “MEIACT,” etc., and expand sales of our generic drugs. We will also work to boost profitability through the global expansion of low-cost operations, and to absorb the impact of drug price revisions. In addition, we will actively undertake R&D and build alliances for a stronger business foundation, resolutely facing challenges in new fields such as anticancer drugs and biosimilars. We will also work to strengthen our reliability assurance structure, and actively expand our international business, focusing on Asia and other emerging markets.

Agricultural Chemicals (agricultural chemicals and veterinary drugs)

In agricultural chemicals, we will foster the business of our “ZAXA” liquid formula foliage herbicide launched in April 2011, and work to boost our cost-competitiveness. We will also implement policies for international business expansion, for example by developing the Korea and Taiwan markets for our “ORYZEMATE” rice blast preventative. In veterinary drugs, we will work to expand the size of our livestock business, and actively develop our companion animal business.

(2) Qualitative Information Concerning Consolidated Financial Position

(i) Assets, Liabilities and Net Assets

[Assets]

Total assets at the end of the consolidated fiscal year under review increased by 33,616 million yen compared to the end of the previous fiscal year, to 749,985 million yen. This was mainly because notes and accounts receivable increased by 22,321 million yen, investment securities increased by 7,285 million yen and total investments and other assets increased by 5,940 million yen.

[Liabilities]

Total liabilities at the end of the consolidated fiscal year under review increased by 28,656 million yen compared to the end of the previous fiscal year, to 451,494 million yen. This was mainly because short-term bank loans decreased by 26,129 million yen and long-term debt decreased by 22,420 million yen, while notes and accounts payable increased by 16,979 million yen, commercial paper increased by 26,000 million yen and bonds increased by 35,000 million yen.

[Net Assets]

Total net assets at the end of the consolidated fiscal year under review increased by 4,960 million yen compared to the end of the previous fiscal year, to 298,491 million yen. This was due to a 2,366 million yen increase in retained earnings, a 2,055 million yen increase in net unrealized holding gains or losses on securities, and a 1,153 million yen increase in minority interests, which offset an unfavorable foreign currency translation adjustment of 1,197 million yen.

The equity ratio was 38.9%, with net assets per share of 3,958.24 yen.

(ii) Cash Flows

(Millions of yen)

	FYE 2011/3	FYE 2012/3	Change
Net cash flow from operating activities	57,995	30,597	-27,397
Net cash flow from investing activities	-32,440	-44,314	-11,874
Net cash flow from financing activities	-19,570	4,861	24,432
Translation adjustment on cash and cash equivalents	-325	-61	264
Net increase (decrease) in cash and cash equivalents	5,658	-8,916	-14,575
Cash and cash equivalents at beginning of year	16,061	21,741	5,680
Increase in cash and cash equivalents from newly consolidated subsidiary	21	1,281	1,260
Increase in cash and cash equivalents resulting from mergers with non-consolidated subsidiaries	—	256	256
Cash and cash equivalents at end of period	21,741	14,363	-7,377

Net cash flow provided by operating activities decreased by 27,397 million yen from the previous consolidated fiscal year to 30,597 million yen. This was due to a decline in income before income taxes and minority interests, and increases in trade receivables and inventories, etc., which exceeded an increase in trade payables, etc.

Net cash flow used in investing activities decreased by 11,874 million yen from the previous consolidated fiscal year, to a negative 44,314 million yen, due primarily to an increase in expenditures for the purchase of investment securities and a decrease in proceeds from sales of investment securities, which exceeded a decrease in expenditures for the acquisition of property, plants and equipment.

This resulted in free cash flow (total of net cash flow from operating activities minus net cash flow used in investing activities) decreased by 39,272 million yen from the previous consolidated fiscal year, to a negative 13,716 million yen.

Net cash flow provided by financing activities increased by 24,432 million yen from the previous consolidated fiscal year, to 4,861 million yen. This was due in part to an increase in financial obligations.

These resulted in 14,363 million yen of cash and cash equivalents at the end of the consolidated fiscal year under review.

Cash flow indices were as follows.

	1st accounting year (FYE 2010/3)	2nd accounting year (FYE 2011/3)	3rd accounting year (FYE 2012/3)
Equity ratio (%)	39.7	40.2	38.9
Equity ratio on market price basis (%)	36.6	34.4	35.5
Debt repayment period	4.2	3.3	6.7
Interest coverage ratio	19.5	24.0	15.0

Note: How to calculate each index is as below.

Equity ratio: (net assets - equity capital held by minority shareholders) / Total assets

Equity ratio on market price basis: Total market value of shares (Closing share price at end of period × total no. of shares issued) / Total assets

Debt repayment period: Interest-bearing debt (bonds, borrowings, commercial paper) / Cash flow from operating activities

Interest coverage ratio: Cash flow from operating activities / Interest payments (amount of interest payments)

*** Forward-looking statements and other special notes**

The above forecasts are based on information currently available at the time of the release of this report and reasonable assumptions made by the Company. Actual results could differ materially from forecasts due to various factors.

2. Management Policy

(1) Basic Policies of Company Management

We work relentlessly to help improve the lifestyles of customers across all generations in the “Food and Healthcare” domains, and are targeting growth and advancement as a world-renowned corporate group, while working to continually enhance value for customers, shareholders and other stakeholders.

1) Group Philosophy

Our mission is to widen the world of “Tastiness and Enjoyment” and meet all expectations regarding “Health and Reassurance.”

Our wish is to be closely in tune with our customers’ feelings and to always be there to brighten their daily lives.

Our responsibility as “Food and Health” professionals is to continue finding innovative ways to meet our customers’ needs, today and tomorrow.

2) Management Attitude

Five Fundamentals

1. Commit ourselves to customer-based ideas and behaviors
2. Provide safe and reassuring high-quality products
3. Strive to always produce new value
4. Foster the development of the synergies and capabilities of the organization and each individual
5. Be a transparent, wholesome company trusted by the society

(2) “Meiji Group 2020 Vision”

Amid ongoing changes in our domestic and overseas business environments, we announced our long-term business roadmap, the “Meiji Group 2020 Vision” (hereinafter referred to as the “2020 Vision”) in September 2010, with the aim of achieving the continuing growth and development of the Meiji Group.

Our 2020 Vision establishes our vision for the group to strive for in FY2020, ending March 31, 2021: “The Meiji Group aims to become a corporate group that brightens customers’ daily lives by providing customers of all ages, from infants to the elderly, with foods that offer tastiness and enjoyment, as well as products that contribute to customers’ physical and emotional well-being.” Our numerical targets are net sales of 1.5 trillion yen and operating income ratio of 5% or higher.

Also, taking into account the competitive environment, business cycles, various regulations, and other considerations, we undertook a corporate reorganization on April 1, 2011. Accordingly, “Meiji Co., Ltd.” (a food company) integrates R&D and a host of other functions, embraces the challenge of creating new value, while leveraging the uniqueness of the confectionery, dairy, health and nutritionals and international businesses, and has a structure that better facilitates the generation of synergies. At Meiji Seika Pharma Co., Ltd. (pharmaceuticals company) meanwhile, we will expedite decision making to create more flexible business operations, and further entrench the “Speciality and Generic Pharmaceuticals Company” concept.

For details on our “2020 Vision” and new management structure, see the URL below.

(<http://www.meiji.com/investor/index.html>)

(3) Medium-Term Business Plan for Fiscal Years 2012-2014 (“TAKE OFF 14”)

Under our new management structure following the corporate reorganization based on our 2020 Vision, we created our “Medium-Term Business Plan for fiscal years 2012-2014 (“TAKE OFF 14”) as our first medium-term business plan. We will work to strengthen existing businesses and foster growth businesses, while actively undertaking thorough compliance, further enhancing our quality assurance system, etc., and engaging in other CSR activities to increase the Meiji Group’s corporate value.

3. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Millions of yen)

	FYE 2011/3 (As of March 31, 2011)	FYE 2012/3 (As of March 31, 2012)
ASSETS		
Current assets		
Cash and deposits	21,759	14,662
Notes and accounts receivable	146,377	168,699
Goods and products	72,654	77,292
Work in process	1,895	2,240
Raw materials and supplies	30,601	32,480
Deferred tax assets	15,138	13,051
Others	13,582	14,387
Allowance for doubtful accounts	-333	-282
Total current assets	301,676	322,531
Fixed assets		
Property, plants and equipment		
Buildings and structures	259,986	270,604
Less accumulated depreciation	-144,267	-149,088
Buildings and structures (net)	115,719	121,515
Machinery and equipment	413,019	423,885
Less accumulated depreciation	-313,204	-322,356
Machinery and equipment (net)	99,814	101,528
Tools and furniture	55,992	56,671
Less accumulated depreciation	-46,274	-47,235
Tools and furniture (net)	9,717	9,435
Land	65,214	65,255
Lease assets	5,796	7,041
Less accumulated depreciation	-1,463	-2,559
Lease assets (net)	4,333	4,482
Construction in progress	18,950	8,966
Total property, plants and equipment	313,750	311,184
Intangible assets		
Goodwill	1,582	270
Other	8,144	7,770
Total intangible assets	9,726	8,040
Investments and other fixed assets		
Investment securities	34,926	42,212
Deferred tax assets	1,182	4,668
Other	55,876	61,816
Allowance for doubtful accounts	-770	-469
Total investments and other fixed assets	91,215	108,228
Total fixed assets	414,692	427,453
Total assets	716,368	749,985

(Millions of yen)

	FYE 2011/3 (As of March 31, 2011)	FYE 2012/3 (As of March 31, 2012)
LIABILITIES		
Current liabilities		
Notes and accounts payable	92,157	109,136
Short-term bank loans	87,989	61,860
Current portion of bonds	—	40,000
Commercial paper	21,000	47,000
Accrued expenses	40,421	42,729
Income taxes payable	3,902	2,888
Accrued bonuses to employees	9,585	9,286
Allowance for sales returns	241	212
Allowance for sales rebates	6,092	5,772
Other current liabilities	39,944	33,612
Total current liabilities	301,333	352,500
Long-term liabilities		
Bonds	55,000	50,000
Long-term debt	28,821	6,401
Deferred tax liabilities	13,661	17,040
Accrued employees' retirement benefits	17,125	18,590
Reserve for directors' retirement benefits	390	417
Other long-term liabilities	6,505	6,544
Total long-term liabilities	121,504	98,994
Total liabilities	422,838	451,494
NET ASSETS		
Shareholders' equity		
Common stock	30,000	30,000
Capital surplus	98,852	98,852
Retained earnings	172,128	174,494
Treasury stock, at cost	-9,255	-9,268
Total shareholders' equity	291,724	294,078
Accumulated other comprehensive income		
Net unrealized holding gains or losses on securities	3,072	5,127
Deferred gains or losses on hedges	-2,899	-2,303
Foreign currency translation adjustments	-4,115	-5,313
Total accumulated other comprehensive income	-3,942	-2,488
Minority interests	5,748	6,901
Total net assets	293,530	298,491
Total liabilities and net assets	716,368	749,985

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

(Millions of yen)

	FYE 2011/3 (April 1, 2010 to March 31, 2011)	FYE 2012/3 (April 1, 2011 to March 31, 2012)
Net sales	1,111,000	1,109,275
Cost of sales	732,931	738,500
Gross profit	378,068	370,774
Selling, general and administrative expenses	348,109	350,584
Operating income	29,959	20,189
Non-operating income		
Interest income	45	54
Dividend income	849	903
Rent income on fixed assets	2,944	2,619
Compensation income	2,000	1,500
Equity in income of affiliates	251	353
Other	1,622	1,648
Total non-operating income	7,713	7,078
Non-operating expenses		
Interest expenses	2,209	1,979
Foreign exchange losses	1,183	282
Rent cost of real estate	2,626	1,963
Other	1,202	1,160
Total non-operating expenses	7,222	5,386
Ordinary income	30,451	21,882
Extraordinary income		
Gain on sale of property, plants and equipment	719	361
Gain on negative goodwill	530	—
Gain on transfer from business divestitures	—	200
Other	549	124
Total extraordinary income	1,799	685
Extraordinary losses		
Loss on disposal of property, plants and equipment	1,782	2,102
Cost of corporate reorganization	1,318	1,951
Loss on disaster	4,980	1,709
Impairment loss	1,992	1,509
Other	4,250	705
Total extraordinary losses	14,325	7,978
Income before income taxes	17,925	14,588
Income taxes-current	9,727	6,902
Income taxes-deferred	-1,388	635
Income taxes-total	8,339	7,537
Income before minority interests	9,586	7,051
Minority interests	34	245
Net income	9,552	6,805

(Consolidated Statements of Comprehensive Income)

(Millions of yen)

	FYE 2011/3 (April 1, 2010 to March 31, 2011)	FYE 2012/3 (April 1, 2011 to March 31, 2012)
Net income before minority interests	9,586	7,051
Other comprehensive income		
Net unrealized holding gains or losses on securities	-2,765	2,070
Deferred gains or losses on hedges	-37	596
Foreign currency translation adjustments	-2,073	-905
Equity in affiliates accounted for by equity method	118	-56
Total other comprehensive income	-4,757	1,703
Comprehensive income	4,828	8,755
(Breakdown)		
Comprehensive income attributable to shareholders of parent company	5,068	8,567
Comprehensive income attributable to minority shareholders	-239	187

(3) Consolidated Statements of Changes in Net Assets

(Millions of yen)

	FYE 2011/3 (April 1, 2010 to March 31, 2011)	FYE 2012/3 (April 1, 2011 to March 31, 2012)
Shareholders' equity		
Common stock		
Balance at the end of previous period	30,000	30,000
Changes during the period		
Total changes during the period	—	—
Balance at the end of current period	30,000	30,000
Additional paid-in capital		
Balance at the end of previous period	98,852	98,852
Changes during the period		
Disposal of treasury stock	0	-0
Total changes during the period	0	-0
Balance at the end of current period	98,852	98,852
Retained earnings		
Balance at the end of previous period	169,618	172,128
Changes during the period		
Cash dividends	-8,844	-5,893
Net income	9,552	6,805
Change of scope of consolidation	1,801	1,037
Change of scope of equity method	—	241
Increase by merger	—	175
Total changes during the period	2,509	2,366
Balance at the end of current period	172,128	174,494
Treasury stock		
Balance at the end of previous period	-9,125	-9,255
Changes during the period		
Acquisition of treasury stock	-139	-16
Disposal of treasury stock	9	3
Total changes during the period	-130	-12
Balance at the end of current period	-9,255	-9,268
Total shareholders' equity		
Balance at the end of previous period	289,345	291,724
Changes during the period		
Cash dividends	-8,844	-5,893
Net income	9,552	6,805
Acquisition of treasury stock	-139	-16
Disposal of treasury stock	9	3
Change of scope of consolidation	1,801	1,037
Change of scope of equity method	—	241
Increase by merger	—	175
Total changes during the period	2,379	2,353
Balance at the end of current period	291,724	294,078

(Millions of yen)

	FYE 2011/3 (April 1, 2010 to March 31, 2011)	FYE 2012/3 (April 1, 2011 to March 31, 2012)
Accumulated other comprehensive income		
Net unrealized holding gains or losses on securities		
Balance at the end of previous period	5,851	3,072
Changes during the period		
Others	-2,779	2,055
Total changes during the period	-2,779	2,055
Balance at the end of current period	3,072	5,127
Deferred gains or losses on hedges		
Balance at the end of previous period	-2,862	-2,899
Changes during the period		
Others	-37	596
Total changes during the period	-37	596
Balance at the end of current period	-2,899	-2,303
Foreign currency translation adjustments		
Balance at the end of previous period	-2,448	-4,115
Changes during the period		
Others	-1,667	-1,197
Total changes during the period	-1,667	-1,197
Balance at the end of current period	-4,115	-5,313
Total accumulated other comprehensive income		
Balance at the end of previous period	540	-3,942
Changes during the period		
Others	-4,483	1,454
Total changes during the period	-4,483	1,454
Balance at the end of current period	-3,942	-2,488
Minority interests		
Balance at the end of previous period	7,885	5,748
Changes during the period		
Others	-2,137	1,153
Total changes during the period	-2,137	1,153
Balance at the end of current period	5,748	6,901
Total net assets		
Balance at the end of previous period	297,771	293,530
Changes during the period		
Cash dividends	-8,844	-5,893
Net income	9,552	6,805
Acquisition of treasury stock	-139	-16
Disposal of treasury stock	9	3
Change of scope of consolidation	1,801	1,037
Change of scope of equity method	—	241
Increase by merger	—	175
Others	-6,620	2,607
Total changes during the period	-4,241	4,960
Balance at the end of current period	293,530	298,491

(4) Consolidated Statements of Cash Flow

(Millions of yen)

	FYE 2011/3 (April 1, 2010 to March 31, 2011)	FYE 2012/3 (April 1, 2011 to March 31, 2012)
Cash flows from operating activities		
Income before income taxes	17,925	14,588
Depreciation and amortization	41,345	40,871
Impairment loss	1,992	1,509
Amortization of goodwill	337	248
Gain on negative goodwill	-530	—
Loss on disposal of property, plants or equipment	1,836	2,088
Loss (gain) on valuation of investment securities	709	227
Increase (decrease) in allowance for doubtful accounts	-733	-350
Increase (decrease) in accrued bonuses to employees	-1,531	-299
Increase (decrease) in employee retirement allowance	-4,830	-3,855
Interest and dividends received	-895	-957
Interest expenses	2,209	1,979
Equity in loss (income) of equity-method affiliates	-251	-353
Loss (gain) on sale of property, plants or equipment	-668	-305
Loss (gain) on sale of investment securities	807	-15
Decrease (increase) in trade receivables	8,898	-22,605
Decrease (increase) in inventories	5,699	-7,234
Increase (decrease) in trade payables	-3,097	16,721
Others	4,541	-1,758
Subtotal	73,765	40,498
Interest and dividends received	989	977
Interest expenses paid	-2,416	-2,034
Income taxes paid	-14,342	-8,843
Net cash provided by operating activities	57,995	30,597
Cash flows from financing activities		
Payments for purchases of property, plants or equipment	-38,512	-35,994
Payments for purchases of intangible fixed assets	-1,999	-2,338
Proceeds from sales of property, plants or equipment and intangible fixed assets	1,833	325
Payments for investments in real estate	-38	-35
Proceeds from sales of investments in real estate	—	520
Payments for purchases of investment securities	-359	-4,351
Proceeds from sales of investment securities	7,478	48
Others	-842	-2,490
Net cash used in investing activities	-32,440	-44,314

(Millions of yen)

	FYE 2011/3 (April 1, 2010 to March 31, 2011)	FYE 2012/3 (April 1, 2011 to March 31, 2012)
Cash flows from financing activities		
Increase (decrease) in short-term bank loans	8,072	-37,490
Increase (decrease) in commercial paper	-7,000	26,000
Proceeds from long-term loans payable	899	519
Repayment of long-term loans payable	-10,974	-11,440
Proceeds from issuance of bonds	—	34,838
Proceeds from stock issuance to minority shareholders	65	—
Expenditure for purchase of shares from minority shareholders	-425	—
Decrease (increase) in treasury stock	-130	-13
Cash dividends paid	-8,774	-5,863
Cash dividends paid to minority shareholders	-136	-119
Others	-1,168	-1,569
Net cash used in financing activities	-19,570	4,861
Translation adjustment on cash and cash equivalents	-325	-61
Net increase (decrease) in cash and cash equivalents	5,658	-8,916
Cash and cash equivalents at beginning of year	16,061	21,741
Increase in cash and cash equivalents from newly consolidated subsidiary	21	1,281
Increase in cash and cash equivalents resulting from mergers with unconsolidated subsidiaries	—	256
Cash and cash equivalents at end of period	21,741	14,363

(5) Notes Concerning the Premise of a Going Concern

Not applicable.

(6) Changes in Significant Matters That Constitute the Basis for Preparation of Consolidated Financial Statements

(Change in scope of consolidation)

A company newly included into scope of consolidation as materiality increased: One

Nitto Co., Ltd.

(Change in scope of application of equity method accounting)

A company newly included into scope of application of equity method accounting as materiality increased: One

CP-MEIJ I Co., Ltd.

(7) Changes in Presentation Methods

(Changes in the method of presenting revenues and expenses of real estate rentals)

Rental revenues related to the real estate rental business were previously posted in net sales. However, starting from the consolidated fiscal year under review, these are posted as rent income on real estate in non-operating income, and related costs are posted as rent cost of real estate in non-operating expenses. Fixed assets related to the real estate rental business were previously posted in property, plants and equipment, but are now posted in investments and other assets. These presentation methods were changed because the importance of the real estate business for

the Meiji Group decreased due to changes in the management structure of the real estate business under the new management structure resulting from the Group reorganization.

Also, the portion of corporate housing costs paid by employees, and rental revenues from rental of part of the headquarters, etc., were posted as rent income on fixed assets as part of non-operating income. Related depreciation, etc. was posted in the cost of sales or in selling, general and administrative expenses. However, starting from the consolidated fiscal year under review, the method was changed, with rental revenues deducted from cost of sales or selling, general and administrative expenses. This is because with the revision of presentation categories of the real estate business, the presentation categories of corporate housing costs, etc. were reconsidered, and consequently the presentation method was changed to clarify the substantial cost burden and more properly present operating income/loss. These changes in presentation method are applied retroactively, with quarterly consolidated financial statements and consolidated financial statements for the previous consolidated fiscal year shown after retroactive application.

As a result, compared to before this retroactive application, net sales for the fiscal year ended March 2011 decreased by 3,094 million yen, while operating income increased by 1,086 million yen. However, there was no impact on ordinary income and income before income taxes. Also, a total of 21,118 million yen in fixed assets relating to rental properties was included in “property, plants and equipment” in the previous consolidated fiscal year, but are now included in the line item “other” under “investments and other fixed assets.” (These assets include 19,767 million yen in buildings and structures, 1,237 million yen in land, and 114 million yen in the “other” category.)

(Consolidated Statements of Income)

In the previous consolidated fiscal year, “Costs related to management integration” included in “Others” of “Extraordinary losses” exceeded 10 percent of total non-operating income. Therefore, it is presented separately starting from the consolidated fiscal year under review. To reflect this change in presentation method, the consolidated financial statements of the previous consolidated fiscal year have been rearranged.

As a result, in the consolidated statements of income of the previous consolidated fiscal year, 5,569 million yen which was presented in “Others” of “Extraordinary losses” has been rearranged as follows: 1,318 million yen in “Costs related to management integration,” and 4,250 million yen in “Others.”

(8) Additional Information

(Application of the Accounting Standards concerning Changes in Accounting and Correction of Errors, etc.)

The “Accounting Standard for Accounting Changes and Error Correction” (ASBJ Statement No. 24; December 4, 2009) and the “Application Guidelines for the Accounting Standard for Accounting Changes and Error Correction” (Corporate Accounting Standards Application Guideline No. 24; December 4, 2009)” are applied for changes in accounting and correction of past errors that have been made since the beginning of the first quarter.

(9) Notes to Consolidated Financial Statements

(Segment Information, etc.)

Segment Information

1. Outline of Reporting Segments

During the fiscal year under review, the Meiji Group executed an internal reorganization within the Group based on an absorption-type split agreement. The reporting segments were changed accordingly, from the previous “Dairy Products,” “Confectionery and Healthcare” and “Pharmaceuticals” segments to the “Food” and “Pharmaceuticals” segments after the change.

The reporting segments of the Meiji Group are the Group’s constituent units for which separate financial information is available and for which the Board of Directors conducts period examinations to determine the allocation of management resources and evaluate business performance.

The Meiji Group has operating subsidiaries organized based on products/services. Operating subsidiaries develop their business activities by formulating comprehensive strategies for Japan and overseas with respect to their products and services.

Consequently, the Meiji Group consists of segments based on operating subsidiaries, with two reporting segments: “Food” and “Pharmaceuticals.”

The “Food” business is handled by Meiji Co., Ltd., and the “Pharmaceuticals” business is handled by Meiji Seika Pharma Co., Ltd.

Each company’s main products are as follows.

Segment	Main Products
Food	Confectioneries, ice cream, sugar and corn sweeteners, fresh dairy, powdered milk, condensed milk, butter, cheese, beverages, nutritional products, healthcare products, OTC drugs, etc.
Pharmaceuticals	Ethical pharmaceuticals, agricultural chemicals, veterinary drugs, etc.

Segment information for the previous fiscal year has been presented in the new segmentation for the sake of comparison. Also, segment information for the previous fiscal year has been presented after the retroactive application of “Changes in the method of presenting revenues and expenses of real estate rentals” described in the section entitled “3. Consolidated Financial Statements ‘(7) Changes in Presentation Methods’.”

2. Methods of Calculating Net Sales, Income (Loss), Assets, Liabilities and Other Items for Each Reporting Segment

Methods of accounting treatment of reported business segments are the same as written in “Significant Changes to the Basis of Presenting Consolidated Financial Statements.”

The profit of a reporting segment is the figure for operating income.

Inter-segment sales and transfers are mainly based on the price of third-party transactions, or on manufacturing costs.

3. Information on Amounts of Net Sales, Income (Loss), Assets, Liabilities and Other Items for Each Reporting Segment

The Previous Consolidated Fiscal Year (April 1, 2010 to March , 2011)

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Statements of Income (Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to third parties	988,037	122,963	1,111,000	—	1,111,000
(2) Inter-segment sales and transfers	817	1,238	2,056	-2,056	—
Total	988,854	124,202	1,113,057	-2,056	1,111,000
Income by Segment	22,322	7,522	29,844	115	29,959
Segment assets	542,986	129,118	672,105	44,263	716,368
Other items					
Depreciation	33,797	5,639	39,436	1,900	41,337
Equity in income of affiliates	1,781	23	1,804	—	1,804
Increase in property, plants and equipment/ intangible fixed assets	39,114	5,738	44,853	44	44,897

(Notes)

1. Details of “Adjustments” are as follows:

The segment income adjustment of 115 million yen includes inter-segment eliminations of 70 million yen and 44 million yen in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

The adjustment of segment assets of 44,263 million yen includes a negative 86,480 million yen inter-segment elimination of assets, and corporate assets of 130,744 million yen not allocated to individual reporting segments. In “Assets,” the main components of corporate assets are the Company’s (the holding company’s) surplus management funds (cash and

deposits), long-term investment funds (investment securities) and the Company's (the holding company's) assets held, etc.

- The segment income is adjusted to the operating income recorded in the consolidated statements of income.

The Consolidated Fiscal Year under Review (April 1, 2011 to March 31, 2012)

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Statements of Income (Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to third parties	985,134	124,140	1,109,275	—	1,109,275
(2) Inter-segment sales and transfers	1,185	1,133	2,318	-2,318	—
Total	986,319	125,274	1,111,593	-2,318	1,109,275
Income by Segment	11,491	8,186	19,678	511	20,189
Segment assets	565,233	131,990	697,223	52,761	749,985
Other items					
Depreciation	34,476	5,169	39,645	1,226	40,871
Equity in income of affiliates	3,080	103	3,183	—	3,183
Increase in property, plants and equipment/intangible fixed assets	34,070	5,793	39,863	84	39,948

(Notes)

- Details of "Adjustments" are as follows:

The segment income adjustment of 511 million yen includes inter-segment eliminations of 94 million yen and 417 million yen in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

The adjustment of segment assets of 52,761 million yen includes a negative 96,236 million yen inter-segment elimination of assets, and 148,998 million yen of corporate assets not allocated to individual reporting segments. The main components of corporate assets are the Company's (the holding company's) surplus management funds (cash and deposits), long-term investment funds (investment securities) and the Company's (the holding company's) assets held, etc.

- The segment income is adjusted to the operating income recorded in the consolidated statements of income.

(Per Share Data)

Previous Fiscal Year (April 1, 2010 to March 31, 2011)	Fiscal Year under Review (April 1, 2011 to March 31, 2012)
Net assets per share 3,906.36 yen	Net assets per share 3,958.24yen
Net income per share 129.63 yen	Net income per share 92.38 yen
Basis for calculating net income per share Net income 9,552 million yen	Basis for calculating net income per share Net income 6,805 million yen
Amount not attributed to common shareholders — million yen	Amount not attributed to common shareholders — million yen
Net income available to shareholders of shares of common stock 9,552 million yen	Net income available to shareholders of shares of common stock 6,805 million yen
Average number of shares of common stock outstanding during the year 73,688 thousands	Average number of shares of common stock outstanding during the year 73,668 thousands

(Note) Diluted net income per share is not given because there are no dilutive shares.

(Significant subsequent events)

Not applicable

May 14, 2012

Consolidated Financial Results for FYE 2012/3 - Supplementary Explanatory Data

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen.)

1. Outline of Consolidated Financial Results

1. Results of Operations (April 1, 2011 to March 31, 2012)

(Billions of yen, % of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income	
		%		%		%		%
FYE 2012/3	1,109.2	-0.2	20.1	-32.6	21.8	-28.1	6.8	-28.8
FYE 2011/3	1,111.0	+0.4	29.9	+4.1	30.4	+7.5	9.5	-27.0

[Reference] FYE 2012/3 Change from the Plan announced on Feb. 13, 2012

(Billions of yen, % of change from the plan)

FYE 2012/3	Net Sales		Operating Income		Ordinary Income		Net Income	
		%		%		%		%
Results	1,109.2	+0.4	20.1	+12.2	21.8	+15.2	6.8	+4.7
Plan (announced on Feb. 13)	1,105.0	-	18.0	-	19.0	-	6.5	-

2. Financial Position

(Billions of yen)

	Total Assets	Net Assets	Equity Ratio (%)	Net Assets per Share (yen)
FYE 2012/3	749.9	298.4	38.9	3,958.24
FYE 2011/3	716.3	293.5	40.2	3,906.36

[Reference] Shareholders' Equity FYE 2012/3: 291.5 billion yen FYE 2011/3: 287.7 billion yen

3. Segment Information (April 1, 2011 to March 31, 2012)

(Billions of yen)

FYE 2012/3	Net Sales		Operating Income	
	Results	YoY Change	Results	YoY Change
Food Segment	986.3	-0.3	11.4	-48.5
Pharmaceuticals Segment	125.2	+0.9	8.1	+8.8
Total for Reporting Segments	1,111.5	-0.1	19.6	-34.1
Adjustments	-2.3	-	0.5	-
Amount Presented in Statements of Income	1,109.2	-0.2	20.1	-32.6

Note: YoY changes are calculated by using figures, assuming for the sake of comparison that the new segmentation has been applied from the start of the previous fiscal year.

[Reference] Food Segment Financial Results by Business

(Billions of yen)

FYE 2012/3	Net Sales	Op. Income
	Results	Results
Dairy	584.5	7.4
Confectionery	299.2	4.1
Healthcare and Nutritionals	117.7	-0.2
Others	179.2	-0.1

Note: Results shown are simply the combined totals before eliminations.

4. Analysis of Operating Income (April 1, 2011 to March 31, 2012)

(Billions of yen)

		by segment			(Ref.) Full-year Plan
		Food	Pharma	Other	
FYE 2011/3	29.9 (*1)	22.3	7.5	0.1	29.9
Due to increased/decreased sales	-2.6 (*2)	-5.2	+2.6	-	-5.6
Procurement costs of raw materials	-2.8	-2.8	0	-	-3.0
Depreciation	-0.8	-0.8	0	-	-0.8
Advertising expenses, etc.	-0.8	-0.8	0	-	-0.6
Cost reduction	-0.8 (*3)	-0.3	-0.5	-	+0.8
Other	-2.2 (*4)	-1.6	-1.1	+0.5	-2.4
Consolidated subsidiaries	+0.2	+0.6	-0.4	-	-0.3
FYE 2012/3	20.1	11.4	8.1	0.6	18.0

Note: Planned figures above are announced on February 13, 2012.

- *1: With the corporate reorganization, the management structure for the real estate business was changed. Therefore, the method of presenting revenues and expenses for real estate rentals has been changed from the fiscal year under review. 29.9 billion yen, operating income for FYE 2011/3, includes 1.1 billion yen as difference caused by retroactive application. caused by retroactive application.
- *2: (Breakdown) [Food] Decrease in income due to decreased sales: -1.6 Worsening of the product mix: -3.5
[Pharma] Increase in income due to increased sales: +2.6
- *3: (Breakdown) [Food] Efficiency in production: +0.5 Efficiency in promotion expenses: +0.8
Efficiency in distribution: -1.3 Other: -0.3
[Pharma] Improvement in cost of sales and decrease in manufacturing overhead costs: +0.4
Increase in promotion expenses: -0.9
- *4: (Breakdown) [Food] Periodic retirement benefit costs: -0.5 Other: -1.1
[Pharma] Increase in R&D expenses: -0.3 Foreign exchange: -0.4 Other: -0.2

5. Major Elements of Selling, General and Administrative Expenses

(Billions of yen)

	FYE 2011/3	FYE 2012/3
Selling, General and Administrative Expenses	348.1	350.5
Carriage and storage charges	45.1	44.6
Sales promotion expenses	121.2	117.7
Labor cost	70.0	72.5

6. Dividends

	Dividends per Share			Payout Ratio (Consolidated)
	Interim	Year-end	Total	
FYE 2012/3	yen 40.00	yen 40.00	yen 80.00	% 86.6

2. Forecast for FYE 2013/3

1. Forecasts of Operations (April 1, 2012 to March 31, 2013)

(Billions of yen)

FYE 2013/3	1st Half		2nd Half		Full-year	
		YoY Change		YoY Change		YoY Change
		%		%		%
Net Sales	560.0	+2.2	565.0	+0.7	1,125.0	+1.4
Operating Income	8.0	+7.9	16.0	+25.2	24.0	+18.9
Ordinary Income	9.0	+3.8	15.0	+13.5	24.0	+9.7
Net Income	4.3	+82.2	7.5	+68.7	11.8	+73.4

2. Forecasts by Business Segment

(1) Net Sales

(Billions of yen)

FYE 2013/3	1st Half	YoY Change		2nd Half	YoY Change		Full-year	YoY Change	
		Amount	Rate		Amount	Rate		Amount	Rate
			%			%			%
Food Segment	503.1	+12.5	+2.6	496.9	+1.1	+0.2	1,000.0	+13.6	+1.4
Dairy	306.0	+13.6	+4.7	289.2	-8.0	-2.7	595.3	+5.6	+1.0
Confectionery	143.5	+0.9	+0.7	153.9	+3.0	+2.0	297.4	+3.9	+1.4
Healthcare and Nutritionals	60.4	+0.9	+1.6	64.6	+6.4	+11.1	125.1	+7.3	+6.3
Others	88.8	-1.6	-1.8	89.5	+0.2	+0.3	178.4	-1.4	-0.8
Adjustments	-	-	-	-	-	-	-	-	-
Pharmaceuticals Segment	58.7	+0.1	+0.2	69.6	+2.8	+4.3	128.3	+3.0	+2.4

(2) Operating Income

(Billions of yen)

FYE 2013/3	1st Half	YoY Change		2nd Half	YoY Change		Full-year	YoY Change	
		Amount	Rate		Amount	Rate		Amount	Rate
			%			%			%
Food Segment	6.4	+3.8	+140.3	12.0	+3.2	+35.9	18.4	+7.0	+60.1
Dairy	6.6	+4.0	+154.9	5.8	-1.5	-20.5	12.4	+2.5	+25.2
Confectionery	0.9	-0.3	-28.1	4.6	+0.7	+20.4	5.5	+0.3	+7.7
Healthcare and Nutritionals	0.0	+0.1	-	1.9	+2.8	-	1.9	+3.0	-
Others	-0.2	-0.8	-	0.5	+0.3	+197.9	0.2	-0.5	-70.4
Adjustments	-0.9	-	-	-0.9	-	-	-1.8	-	-
Pharmaceuticals Segment	1.4	-2.9	-67.6	4.0	+0.2	+3.5	5.4	-2.7	-34.0

Note1: Results shown are simply the combined totals before eliminations.

Note2: There will be a partial revision of the expense allocation rules, which serve as the basis for determining the allocation of expenses for each business in the Food segment, effective from the fiscal year ending March 31, 2013.

Also, the segmentation of Dairy business and Confectionery business will be partly revised.

The percentage figures appearing as the percentage of year-on-year change were calculated using previous-year figures retroactively adjusted following the revision in expense allocation rules.

Note3: Food segment adjustments not allocated to individual reporting segments are treated as corporate expenses for Meiji Co., Ltd.

4. Analysis of Operating Income (April 1, 2012 to March 31, 2013)

(1) 1st Half

(Billions of yen)

	Consolidated Total	Food	Phama	Other
FYE 2012/3	7.4	2.6	4.3	0.5
Due to increased/decreased sales	+9.7	+8.1	+1.6	-
Pharmaceutical price modifications	-3.4	-	-3.4	-
Procurement costs of raw materials	-0.6	-0.6	0	-
Cost reduction	+1.5	+1.3	+0.2	-
Sales promotion and advertising expenses	-5.2	-5.2	0	-
Other	-1.5	+0.2	-1.4	-0.3
Consolidated subsidiaries	+0.1	0	+0.1	-
Total change	+0.6	+3.8	-2.9	-0.3
FYE 2013/3	8.0	6.4	1.4	0.2

(2) 2nd Half

(Billions of yen)

	Consolidated Total	Food	Phama	Other
FYE 2012/3	12.7	8.8	3.8	0.1
Due to increased/decreased sales	+12.2	+7.3	+4.9	-
Pharmaceutical price modifications	-3.7	-	-3.7	-
Procurement costs of raw materials	-1.2	-1.2	0	-
Cost reduction	-0.4	-0.5	+0.1	-
Sales promotion and advertising expenses	-3.7	-2.9	-0.8	-
Other	-0.5	0	-0.4	-0.1
Consolidated subsidiaries	+0.6	+0.5	+0.1	-
Total change	+3.3	+3.2	+0.2	-0.1
FYE 2013/3	16.0	12.0	4.0	0.0

(3) Full-year

(Billions of yen)

	Consolidated Total	Food	Phama	Other
FYE 2012/3	20.1	11.4	8.1	0.6
Due to increased/decreased sales	+21.9	+15.4	+6.5	-
Pharmaceutical price modifications	-7.1	-	-7.1	-
Procurement costs of raw materials	-1.8	-1.8	0	-
Cost reduction	+1.1	+0.8	+0.3	-
Sales promotion and advertising expenses	-8.9	-8.1	-0.8	-
Other	-2.0	+0.2	-1.8	-0.4
Consolidated subsidiaries	+0.7	+0.5	+0.2	-
Total change	+3.9	+7.0	-2.7	-0.4
FYE 2013/3	24.0	18.4	5.4	0.2

2. Other

1. Capital Expenditures, Depreciation, R&D Expenses

(Amounts appearing in the table below have been rounded off to nearest 100 million yen)

	FYE 2011/3	FYE 2012/3	FYE 2013/3 (Plan)	Notes
Capital Expenditures	38.5	35.9	59.8	Cash basis (including leases)
Food Segment	-	31.2	53.2	
Pharmaceutical Segment	-	4.6	6.6	
Corporate or Elimination	-	0.0	0.0	
Depreciation	39.0	37.9	38.2	Property, plants and equipment (including leases)
Food Segment	-	31.8	31.6	
Pharmaceutical Segment	-	4.9	5.3	
Corporate or Elimination	-	1.2	1.3	
R&D Expenses	23.4	23.8	24.5	
Food Segment	-	10.6	11.0	
Pharmaceutical Segment	-	13.2	13.5	
Corporate or Elimination	-	0.0	0.0	

Note: Our reporting segments have been changed to Food and Pharmaceuticals since FYE 2012/3.


2. List of New Products Under Development

Stage	Name	Type	Efficacy Classification	Notes
NDA	MEIACT MS® FINE GRANULES 10% (Cefditoren pivoxil)	Oral	Antibiotic	In-house (New Dosage)
	ME2080 (Stiripentol)	Oral	Antiepileptic	In-license: Biocodex (France)
Phase II	REFLEX® (Mirtazapine)	Oral	Fibromyalgia treatment (Additional indications)	In-license: MSD K.K. (formerly, Nippon Organon K.K.)
	ME2112 (Ziprasidone)	Oral	Antipsychotic	In-license: RaQualia Pharma Inc.
Phase I	ME1071	Injection	Metallo-β-lactamase inhibitor (co-administration drug with antibacterials)	In-house
	ME3113 (Udenafil)	Oral	Benign prostatic hyperplasia treatment	In-license: Dong-A Pharmaceutical Co.,Ltd. (Korea)
Phase I (Overseas)	AM-831	Oral	Antipsychotic	In-license: ACADIA Pharmaceuticals (US)

3. Notice concerning Disclosure of FYE 2012/3 Financial Results

1. Changes in Segmentation due to Corporate Reorganization, and the Information to Be Disclosure

In connection with our corporate reorganization in fiscal year ended March 31, 2012 (effective April 1, 2011), our reporting segments have been changed to "Food" and "Pharmaceuticals." (See the diagram below for details.)



Note1: The "Pharmaceuticals Segment," which was previously the pharmaceuticals unit of the former Meiji Dairies Corporation before the changes in segmentation, has been transferred to the Healthcare & Nutritional Business Unit of Meiji Co., Ltd.

Note2: The real estate business of the former Meiji Seika Kaisha Ltd. is not included in segment information due to changes in accounting arrangements.

2. Reclassification for the results for fiscal year ended March 31, 2011 with the change in method of presenting financial statements

With the corporate reorganization, the management structure for the real estate business was changed. Therefore, the method of presenting revenues and expenses for real estate rentals was changed. As a result, the figures after retroactive application are shown for the previous consolidated fiscal year ended March 31, 2011.

Consequently, all figures for FYE 2011/3 in this document are the figures after the reclassification.